Background: Human papillomavirus (HPV), the most prevalent sexually transmitted infection
globally, is a key risk factor for high-grade cervical lesions and cervical cancer. Since 2009 …

Purpose Approximately 70% of cervical cancers and about 50% of high-grade cervical
precursor lesions are caused by human papillomavirus (HPV) types 16 and 18. Denmark …

Human papillomavirus (HPV) vaccines protect against infections with the most oncogenic
HPV types, cervical intraepithelial neoplasia (CIN) and cervical cancer. We investigated …

Background In clinical trials, vaccines against human papillomavirus (HPV) have been
highly effective against HPV16-or HPV18-associated cervical lesions. The quadrivalent HPV …

It is valuable to establish a population‐based prevaccination baseline distribution of human
papillomavirus (HPV) types among women with high‐grade cervical intraepithelial …

Human papillomavirus (HPV) types 16/18, included in HPV vaccines, contribute to the
majority of cervical cancer, and a substantial proportion of cervical intraepithelial neoplasia …

Background Human papillomavirus (HPV) immunisation with a bivalent vaccine (Cervarix)
was introduced in England, UK, in Sept 1, 2008: routine vaccination was offered to girls …

Aim: This study aimed to follow the impact of human papillomavirus (HPV) catch-up and
vaccination on the very high cervical HPV-prevalence in women at a youth clinic in central …

In Norway, single-cohort vaccination with quadrivalent human papillomavirus (qHPV)
vaccine targeting 12-year-old girls took place in 2009–2016. In 2020, the oldest vaccinated …

Background Early effects of HPV (human papillomavirus) vaccination are reflected by
changes observable in young women attending cervical cancer screening. Subject and …